Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, ESPR said it has hit 100% MACE-4 accumulation.
Source: seekingalpha.com